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Abstract
Background: The poor prognosis and the limited efficacy of targeted therapy in patients with triple-negative breast
cancer (TNBC) have raised the need for alternative therapies. Recent studies have demonstrated that folate receptor-alpha
(FRα) may represent an ideal tumor-associated marker for immunotherapy for TNBC.
Methods: The aim of the present study was to apply a chimeric antigen receptor (CAR) approach for the targeting of FRα
expressed on TNBC cells and evaluate the antitumor activity of CAR-engineered T cells in vitro and in vivo.
Results: We found that human T cells expressing a FRα-specific CAR were potent and specific killers of TNBC cells that
express moderate levels of FRα in vitro and significantly inhibited tumor outgrowth following infusion into
immunodeficient mice bearing an MDA-MB-231 tumor xenograft. However, the antitumor activity of the FRα
CAR T cells was modest when compared to the same CAR T cells applied in an ovarian tumor xenograft model
where FRα expression is more abundant. Notably, FRα CAR T cells induced superior tumor regression in vivo
against MDA-MB-231 that was engineered for overexpression of FRα.
Conclusions: Taken together, our results show that FRα CAR T cells can mediate antitumor activity against
established TNBC tumor, particularly when FRα is expressed at higher levels. These results have significant
implications for the pre-selection of patients with high antigen expression levels when utilizing CAR-based
adoptive T cell therapies of cancer in future clinical trials.
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Background
Triple-negative breast cancer (TNBC) is characterized by
the limited expression of the human epidermal growth
factor receptor 2 (HER2), estrogen receptor (ER), and pro-
gesterone receptor (PR) and accounts for approximately
15 % of invasive breast cancers. Patients with TNBC do
not benefit from HER2-based targeted therapy or endo-
crine therapy [1]. Chemotherapy is currently the mainstay
of systemic medical treatment, although patients with
TNBC have a worse outcome after chemotherapy com-
pared to breast cancer patients with other subtypes [2], a
finding that reflects the intrinsically adverse prognosis as-
sociated with the disease. Thus, new and powerful therap-
ies are urgently needed for TNBC patients.
A number of potential antigen targets have been vali-
dated in TNBC [3]. Folate receptor-alpha (FRα) is highly
expressed in non-mucinous tumors of epithelial origin in-
cluding ovarian, breast, and lung cancers and expressed at
low levels on the apical surface of a subset of polarized
epithelial cells including the parotid, kidney, lung, thyroid,
and breast. Specific overexpression of FRα in certain ma-
lignancies, including TNBC [4], with low coordinate ex-
pression in normal tissue, makes FRα an attractive target
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for directed therapies. In breast cancer, FRα expression
can be regulated by steroid hormones, particularly es-
trogens [5, 6]. Specifically, 17β-estradiol has been dem-
onstrated to down-regulate FRα expression by direct
action of the ER on the P4 promoter of FRα, suggesting
a negative correlation between the expression of ER
and FRα. Indeed, O’Shannessy et al. demonstrated that
ER-negative breast cancer samples were significantly more
likely to express FRα than ER-positive cancers. Taken to-
gether, these findings rationalize the assessment of FRα as
a tumor-associated antigen candidate for the targeted
therapy of TNBC.
Given its cancer-centric overexpression, FRα has been
an attractive candidate for targeted drug delivery using
folate-conjugated therapeutic compounds that bind FRα
or murine, chimeric, and humanized monoclonal anti-
bodies (mAbs) alone or in conjugates to deliver radionu-
clides, T cells, and stimulatory cytokines to malignant
tissue [7, 8]. Additionally, the transfer of T cells genetically
redirected with a chimeric antigen receptor (CAR) specific
for FRα is an attractive technology that is actively being
investigated [9, 10]. The CAR approach combines the
antigen specificity of an antibody with the ability of T cells
to mediate the killing of tumor cells in a single fusion mol-
ecule. CAR-modified T cells actively and specifically target
their specified antigen and have the capacity to persist as
memory cells in vivo [9, 10]. As such, CAR-modified T
cells that target tumor-associated antigens (TAAs), such
as FRα, may be more effective than mAbs in generating
durable tumor responses. Here, we generated a FRα-
specific CAR with an intracellular CD27 co-stimulatory
signaling domain and evaluated the therapeutic efficacy of
T cells transduced to express this CAR in a murine xeno-
graft model of human TNBC. We demonstrate that FRα-
specific CAR T cells have the capacity to inhibit human
TNBC growth in vivo and that more robust tumor regres-




Lentivirus packaging was executed using the immortalized
normal fetal renal 293T cell line purchased from ATCC.
Human cell lines used in immune-based assays include the
established human ovarian cancer cell lines SKOV3 and
C30 and breast cancer cell lines T47D, SKBR3, MCF7,
MDA-231, MDA-436, MDA-468, MDA-453, and BT549.
For bioluminescence assays, the cancer cell lines were
transfected to express firefly luciferase (fLuc). The mouse
malignant mesothelioma cell line, AE17 (kindly provided
by Steven Albelda, University of Pennsylvania), was used
as antigen negative control. All cell lines were maintained
in R10 medium: RPMI-1640 supplemented with 10 %
heat-inactivated FBS, 100 U/mL penicillin, 100 mg/mL
streptomycin sulfate, and 10 mmol/L HEPES.
CAR construction and lentivirus production
The anti-FRα CAR construct was comprised of the MOv19
scFv linked to a CD8a hinge and transmembrane region,
followed by a CD3z signaling moiety in tandem with the
CD27 intracellular signaling motif (MOv19-27z; Fig. 1a)
and was previously described [9, 10]. An anti-CD19 CAR
containing CD3z and CD27 signaling motifs in tandem
(CD19-27z) was used as an antigen specificity control
[9, 11]. High-titer replication-defective lentiviruses were
produced and concentrated as previously described [12].
Briefly, 293T cells were seeded in 150-cm2 flask and trans-
fected using Express In (Open Biosystems) according to
the manufacturer’s instructions. FRα-specific CAR trans-
gene plasmids (15 μg) were co-transfected with 18 μg
pRSV.REV (Rev expression plasmid), 18 μg pMDLg/p.RRE
(Gag/Pol expression plasmid), and 7 μg pVSV-G (VSV
glycoprotein expression plasmid) with 174 μL Express In
(1 μg/μL) per flask. Supernatants were collected at 24 and
48 h after transfection, concentrated 10-fold by ultracentri-
fugation for 2 h at 28,000 rpm with a Beckman SW32Ti
rotor (Beckman Coulter). The viruses were aliquoted into
tubes and stored at −80 °C until ready to use for titering or
experiments. All lentiviruses used in the experiments were
from concentrated stocks.
Human T cells and transfection
Primary human T cells, purchased from the Human Im-
munology Core at University of Pennsylvania, were iso-
lated from healthy, normal donors following leukapheresis
by negative selection. All T cell samples were collected
under a protocol approved by a University Institutional
Review Board, and written informed consent was obtained
from each healthy, normal donor. T cells were cultured in
R10 medium and stimulated with anti-CD3 and anti-
CD28 monoclonal antibody (mAb)-coated beads (Invitro-
gen). Approximately 18 to 24 h after activation, human T
cells were transduced using a spinoculation procedure.
Briefly, 0.5 × 106 T cells were infected with a multiplicity of
infection (MOI) of 5 of the MOv19-27z vector. A mixture
of cells and vectors were centrifuged at room temperature
for 90 min (2500 rpm) in a table-top centrifuge (Sorvall
ST 40). After the engineered T cells were rested, as deter-
mined by decreased growth kinetics and cell size which
is measured using the Multisizer 3 Coulter Counter
(Beckman Coulter), the rested T cells were then used
for functional analysis.
Flow cytometric analysis
The following fluorochrome-conjugated mAbs, purchased
from BD Biosciences, were used for phenotypic analysis:
APC-Cy7 anti-human CD3, fluorescein isothiocyanate
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(FITC) anti-human CD4, APC anti-human CD8, PE-
anti-human CD45, and PE anti-human CD137. 7-Ami-
noactinomycin D (7-AAD) was used for viability staining.
For the in vivo mouse T cell transfer experiments, periph-
eral blood was obtained via retro-orbital bleeding and
stained for the presence of human CD45, CD4, and CD8
T cells. Gating specifically on the human CD45+ popula-
tion, the CD4+ and CD8+ subsets were quantified using
TruCount tubes (BD Biosciences) with known numbers of
fluorescent beads as described in the manufacturer’s in-
structions. Tumor cell lines and enzymatically digested
MDA-231 tumor cell surface expression of FRα was mea-
sured using human PE-FRα mAb (R&D Systems, Inc.) and
Quanti-Brite PE beads (BD Bioscience). The FRα PE-
conjugated antibody was used at a 1:1 PE/protein ratio for
the quantitative analysis of surface FRα expression. FRα
antigen copy number per tumor cell was evaluated by
comparing the mean fluorescence intensity (MFI) versus
the number of known PE molecules per bead. A calibra-
tion curve was constructed per cell line to calculate the
mean number of PE molecules per cell for the FRα+ cell
population. Mouse mesothelioma cell line AE17 was used
as a negative control, and the background human FRα re-
ceptors/cell values measured on AE17 were subtracted
from the FRα receptors/cell values detected on breast can-
cer cell lines.
FRα CAR surface expression was evaluated using re-
combinant FRα-Fc protein (R&D Systems) followed by
PE-labeled anti-human IgG Fc gamma-specific antibody
(eBioscience) or biotin-labeled goat anti-mouse IgG F(ab′)2
fragment followed by streptavidin-APC. For intracellular
cytokine staining, T cells were stimulated in R10 media
containing phosphomolybdic acid (PMA) (30 ng/mL)
(Sigma-Aldrich), ionomycin (500 ng/mL) (Sigma-Al-
drich), and monensin (GolgiStop) (1 μL/mL) (BD Bio-
sciences) in a cell incubator with 10 % CO2 at 37 °C for
4 h. Cytokine production in CAR T cells was determined
by co-culturing CAR T cells with FRαpos ovarian cancer
cells for 5 h. After the cell surface markers were stained,
the cells were then fixed and permeabilized using Cytofix/
Cytoperm and Perm/Wash buffer (eBioscience) according
to the manufacturer’s instructions. The cells were then
Fig. 1 Construction and expression of folate receptor-alpha (FRα)-specific chimeric antigen receptor (CAR). a Schematic representation of MOv19-
based FRα CAR constructs containing the CD27 co-stimulatory module in combination with the CD3ζ cytosolic domain. b Primary human CD3 T
cells can efficiently express FRα-specific CAR. Expression was detected via PE-conjugated goat anti-mouse F(ab′)2 fragment and measured by flow
cytometry. c Compared to untransduced (UNT) T cells, transduced T cells consisted of CD4- and CD8-positive cells with both subsets expressing
FRα CAR. FRα CAR expression was detected via biotin-labeled recombinant FRα protein staining followed by streptavidin-PE after transduction
with lentivirus. Transduction efficiencies are indicated with the percentage of CAR expression in parentheses
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stained with the following fluorescence-conjugated cytokine
antibodies: PE anti-human interferon-gamma (IFN-γ), Pa-
cific Blue anti-human TNF-α, and FITC anti-human IL-2.
All flow cytometry was conducted using a BD FACSCanto
II flow cytometer (BD Biosciences), and flow cytometric
data were analyzed with FlowJo version 7.6.1 software (Tree
Star, Ashland, OR).
Cytokine release assays
Cytokine release assays were performed by co-culturing
1 × 105 T cells with 1 × 105 target cells in triplicate in a
96-well flat bottom plate in a total volume of 200 μL
R10 media. After 20–24 h, co-culture supernatants were
collected and ELISA (Biolegend, San Diego) was per-
formed, according to the manufacturer’s instructions, to
measure the secretion of IFN-γ. The values shown rep-
resent the mean of triplicate wells.
Cytotoxicity assays
For cell-based bioluminescence assays, 5 × 104 firefly lu-
ciferase (fLuc)-expressing tumor cells were cultured with
R10 media in the presence of different T cell ratios in a
96-well Microplate (BD Biosciences). After incubation
for ~20 h at 37 °C, each well was filled with 50 μL of
DPBS resuspended with 1 μL of D-luciferin (0.015 g/mL)
and imaged with the Xenogen IVIS Spectrum. Tumor cell
viability percentage was calculated as the mean lumines-
cence of the experimental sample minus background di-
vided by the mean luminescence of the input number of
target cells used in the assay minus background times 100.
All data are represented as a mean of triplicate wells.
Xenograft model of TNBC and ovarian cancer
All animals were obtained from the Stem Cell and
Xenograft Core of the Abramson Cancer Center, Uni-
versity of Pennsylvania. NOD/SCID/γ-chain−/− (NSG) mice
(6–12 weeks old) were bred, treated, and maintained under
pathogen-free conditions in-house under University of
Pennsylvania IACUC-approved protocols. To establish a
TNBC model, 6- to 12-week-old female NSG mice were
inoculated subcutaneously (s.c.) on the flank with 3 × 106
MDA-231 fLuc+ or MDA-231.FR fLuc cells on day 0. For
the ovarian cancer model, NSG mice were inoculated s.c.
on the flank with 5 × 106 SKOV3 fLuc+ cells. After the tu-
mors become palpable at about 3 weeks, primary human T
cells were activated and transduced as described above.
After the primary human Tcells were expanded for 2 weeks
and the mouse tumor burden was about 200–300 mm3,
the mice were treated with the T cells. The route, dose, and
timing of T cell injections are indicated in the individual
figure legends. Tumor dimensions were measured with
calipers and tumor volumes calculated using the formula
V = 1/2(length ×width2), where length is the greatest longi-
tudinal diameter and width is the greatest transverse
diameter. Animals were imaged prior to T cell transfer and
about every week thereafter to evaluate tumor growth.
Photon emission from fLuc+ cells was quantified using
the “Living Image” software (Xenogen) for all in vivo ex-
periments. Approximately 40 days after the first T cell
injection, the mice were euthanized and the tumors were
resected immediately in order to calculate the tumor
volumes.
Bioluminescence imaging
Tumor growth was also monitored using bioluminescence
imaging (BLI). BLI was conducted using Xenogen IVIS im-
aging system. The photons emitted from fLuc-expressing
cells within the animal body were quantified using Living
Image software (Xenogen). Briefly, mice bearing MDA-231
fLuc+ or MDA-231.FR fLuc+ tumor cells were injected in-
traperitoneally (i.p.) with D-luciferin (150 mg/kg stock,
100 μL of D-luciferin per 10 g of mouse body weight) sus-
pended in PBS and imaged under isoflurane anesthesia
after 5~10 min. A pseudocolor image representing light in-
tensity (blue, least intense; red, most intense) was gener-
ated using Living Image. BLI findings were confirmed at
necropsy.
Statistical analysis
The data are reported as means and standard deviations
(SDs). Statistical analysis was performed using two-way
repeated-measure analysis of variance (ANOVA) for the
tumor burden (tumor volume, photon counts). Student’s
t test was used to evaluate differences in absolute num-
bers of transferred T cells, cytokine secretion, and spe-
cific cytolysis. GraphPad Prism 5.0 (GraphPad Software)
was used for the statistical calculations, where a p value
of p < 0.05 was considered significant.
Results
Construction and expression of FRα-specific CAR
A FRα-specific CAR-encoding lentivirus construct was
generated comprised of the anti-human FRα-specific
MOv19 scFv [13] linked to a CD8α hinge and trans-
membrane region, followed by a CD27 intracellular sig-
naling motif in tandem with the CD3ζ signaling moiety,
and referred to as MOv19-27z (Fig. 1a). Primary human
CD3+ T cells were efficiently transduced with CAR lenti-
viral vectors with reproducible transduction efficiencies of
~80 % (Fig. 1b). Surface expression of the FRα CAR on
CD4+ and CD8+ Tcells was detectable using recombinant
FRα protein staining (Fig. 1c), demonstrating positive
CAR expression and antigen binding capacity.
FRα is expressed on the surface of TNBC cell lines
Using flow cytometry, surface expression of FRα protein
was determined on a variety of tumor cell lines after
staining the cells with anti-FRα antibody. FRα expression
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was detected in ovarian cancer lines SKOV3 and A1847 at
high levels and also on the breast cancer cell lines, T47D,
SKBR3, and MCF7; the C30 ovarian cancer cell line served
as an antigen negative control (Fig. 2). Importantly, all five
TNBC cell lines tested, including MDA-231, MDA-468,
MDA-436, MDA-453, and BT549, expressed FRα protein
on their cell surface at moderate to low levels (Fig. 2). As
demonstrated in Additional file 1: Figure S1A, there was a
range of FRα molecules expressed per cell among the
breast cancer cell lines tested.
FRα CAR T cells specifically recognize FRαpos TNBC cell
lines in vitro
To determine whether human FRα CAR-modified T cells
were able to recognize and react against FRαpos TNBC
cells, FRα CAR-bearing T cells were co-cultured overnight
with the TNBC cell lines MDA-231, MDA-468, MDA-436,
MDA-453, or BT549, and IFN-γ secretion in the cell cul-
ture supernatants was measured by ELISA. Since ovarian
cancers and breast cancers frequently express FRα, estab-
lished human ovarian cancer cell lines (SKOV3) and breast
cancer cell lines (T47D, SKBR3, and MCF7) that express
surface FRα at varying levels were used for positive control
targets, while FRα-negative cell lines C30 and AE17 were
used as negative controls. As shown in Fig. 3a, FRα CAR T
cells secreted substantial amounts of IFN-γ, denoting T cell
activation after co-culture with FRαpos TNBC cell lines.
The number of FRα molecules/cells correlated with the
amount of IFN-γ secreted (Additional file 1: Figure S1B)
and determined the coefficient of determination value
(R2 = 0.62). No IFN-γ production was detected when
FRα CAR T cells were cultured with FRα-negative
targets (C30 and AE17) or from co-cultures containing
untransduced (UNT) T cells. Up-regulated CD137 (4-1BB)
expression represents a surrogate marker for antigen-
specific activation of functional human CD8+ T cells [14].
When FRα CAR T cells were co-cultured with FRαpos or
FRαneg tumor cells, robust up-regulation of CD137 by CAR
T cells was observed only when incubated with FRαpos
TNBC cells (Fig. 3b). CD137 up-regulation was not de-
tected on anti-CD19 CAR T cells when similarly cul-
tured with FRαpos TNBC cells, indicating that CD137
up-regulation by FRα CAR T cells was antigen-specific.
In addition to the above assays, representative
fluorescence-activated cell sorter (FACS) plots of 5-h
intracellular expression of proinflammatory cytokines by
FRα CAR T cells in response to FRαpos TNBC cells are
shown (Fig. 3c). Th1 cytokines including IFN-γ, TNF-α,
and IL-2 were exclusively expressed in FRα CAR T cells
and not in UNT control T cells, when incubated with the
FRαpos MDA-231 TNBC cell line. PMA/ionomycin-
treated T cells served as positive controls for T cell-
stimulated cytokine production.
FRα CAR T cells have antitumor activity against MDA-231
in vitro and in vivo
The cytolytic activity of FRα CAR T cells in vitro was eval-
uated using an overnight bioluminescence assay (Fig. 4a).
FRα CAR T cells had robust and specific cytotoxic activity
against FRαpos MDA-231 cells but not FRα-negative C30
cells. Untransduced or control anti-CD19 CAR T cells did
not lyse MDA-231 or C30 cell lines.
To assess the antitumor activity of CAR T cells target-
ing FRαpos tumor in vivo, we first evaluated the potency
Fig. 2 FRα may represent a new therapeutic target in TNBC. FRα surface expression in TNBC cell lines was measured by flow cytometry. FRα-specific
mAb MOv18 was used to measure FRα expression on various ovarian cancer (OC) and breast cancer (BC) cell lines (open empty histogram), compared
to a matched isotype antibody control (filled gray histogram)
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of FRα CAR T cells using a xenograft mouse model of
TNBC tumor. Immunodeficient non-obese diabetic/se-
vere combined immunodeficient/IL-2γcnull (NSG) mice
received subcutaneous inoculation of firefly luciferase
(fLuc+) FRαpos human TNBC MDA-231 cells on the
hind flank and received intravenous (I.V.) injections of
107 CAR+ T cells on days 40 and 46 after tumor inocu-
lation, when tumors were ~250 mm3 in size and evident
by bioluminescence imaging (BLI). Infused FRα-specific
MOv19-27z CAR T cells mediated significant, albeit mod-
est, reduction in tumor progression compared to the con-
trol mice treated with untransduced T cells (p = 0.01) or
with anti-CD19 CAR T cells (p = 0.035), as measured by
caliper-based tumor size (Fig. 4b).
We next measured the persistence of the transferred hu-
man Tcells in vivo to determine whether modest antitumor
activity was associated with poor T cell engraftment. Per-
ipheral blood was obtained from MDA-231-bearing NSG
mice treated with IV injections of T cells on day 60, 14 days
after the last dose of transferred T cells, and quantified for
the presence of human CD4+ and CD8+ T cells. Mice that
received FRα-specific MOv19-27z T cells had readily de-
tectable circulating human CD4+ and CD8+ T cells with
significantly higher cell counts than those observed in
mice treated with anti-CD19 CAR or untransduced T cells
(Fig. 4c; p = 0.008 and p = 0.002, respectively), indicating
that tumor antigen recognition drives the survival of the
adoptively transferred FRα-specific CAR T cells in vivo.
Fig. 3 FRα CAR T cells secrete Th1 cytokines and up-regulate CD137 in response to FRα (+) tumor cells. a IFN-γ secretion of FRα CAR-transduced
T cells after 20 h co-culture with the indicated tumor lines at a 1:1 ratio. Untransduced (UNT) T cells were used as a negative control. b Antigen-specific
T cell activation was detected by the induction of CD137 expression. c FRα CAR T cells were stimulated with MDA-231 cells for 5 h in the presence of
Golgi stop and analyzed by flow cytometry for intracellular cytokines IFN-γ, TNF-α, and IL-2. UNT T cells served as our negative control, whereas PMA
and ionomycin-treated T cells served as positive controls
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We next assayed for FRα protein expression on residual
tumors after treatment with untransduced, anti-CD19
CAR or FRα-specific CAR T cells, to determine whether
tumor outgrowth in FRα CAR-treated mice was a bypro-
duct of immune pressure and selective growth of FRα-
negative cancer cells. MDA-231 tumors retained a stable
FRα expression profile (Additional file 2: Figure S2), indi-
cating that antigen loss did not occur after CAR T cell
treatment in this TNBC xenograft model.
FRα CAR T cells preferentially kill antigen overexpressing
tumor cells
We previously showed that FRα CAR T cells can eradicate
FRαpos ovarian cancer xenografts in vivo [9, 10] and that
FRα expression on MDA-231 cells is sufficient for recog-
nition by FRα CAR T cells in vitro and in vivo. In parallel
assays, we observed superior tumor regression in a FRαpos
SKOV3 ovarian cancer xenograft model where mice were
treated with the same FRα CAR T cells (Additional file 3:
Figure S3), reflecting a disparity in the killing of TNBC
MDA-231 tumors versus FRαpos SKOV3 ovarian tumors
in vivo. We postulated that this resulted from the higher
relative expression of FRα protein by SKOV3 than MDA-
231, which reduced the potential of CAR T cells to exert
their full function against TNBC in vivo and that TNBC
cells with higher FRα expression might be more respon-
sive to therapy. To test this hypothesis, MDA-231 cells
were engineered to overexpress human FRα (referred to
as MDA-231.FRα). The MDA-231.FRα cell line exhibited
a 19-fold increase in mean fluorescence intensity for FRα
expression compared to the parental line (Fig. 5a). In an
in vitro cytotoxicity assay, FRα CAR T cells were capable
of killing MDA-231.FRα cells as well as SKOV3 cells and
more efficiently than parental MDA-231 cells (Fig. 5b).
Untransduced T cells served as a negative control and did
not recognize or kill tumor cells despite the high levels of
FRα expression. Thus, it appears that tumor cells express-
ing antigen at low levels are less sensitive to killing by
CAR T cells. We therefore sought to determine whether
CAR T cells preferentially kill tumor cells that express
antigen at higher levels and selectively spare tumor cells
with lower FRα levels. We first engineered parental MDA-
231 cells that express moderate levels of FRα to express
green fluorescent protein (GFP), referred to as MDA-
231.GFP, and then co-cultured MDA-231.FRα (GFP-nega-
tive) cells with MDA-231.GFP cells at a 1:1 ratio, where
~50 % of all MDA-231 cells were found to express GFP
(Fig. 5c). The 1:1 MDA-231 mixture was then exposed to
either untransduced or FRα-specific CAR T cells at a tar-
get to effector cell ratio of 1:3 for 24 h. Treatment with
FRα CAR T cells resulted in a relative increase in the
number of MDA-231.GFP-engineered tumor cells (~85 %
GFPpos), reflecting a selective killing of the GFP-negative,
FRα overexpressing MDA-231.FRα cell population (Fig. 5c).
Fig. 4 Anti-tumor activity of FRα CAR T cells in vitro and in vivo. a FRα CAR T cells lysed FRα+ MDA-231 cells but exhibited decreased lysis of the
FRα-C30 cells at the indicated effector/target (E/T) ratio for ~20 h. Untransduced (UNT) T cells served as our negative control. b NSG mice bearing
established subcutaneous (s.c.) tumor were treated with intravenous (i.v.) injections of 1 × 107 CAR+ T cells on days 40 and 46 post tumor inoculation.
Tumor growth was assessed by caliper measurement [V = 1/2(length ×width2)]. c Peripheral blood was collected 3 weeks after the first T cell infusion
and quantified for the absolute number of human CD4+ and CD8+ T cells/μL of blood. Mean cell count ± SEM is shown with n = 5 for all groups
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As anticipated, untransduced T cell treatment had no im-
pact when co-cultured with tumor cells with ~50 % of
MDA-231 cells still expressing GFP. These results suggest
that tumor cells expressing higher antigen levels are prefer-
entially killed, relative to those with lower target antigen
expression.
FRα CAR T cells induce rapid tumor regression of TNBC
overexpressing FRα in vivo
To evaluate the impact of the antigen level on antitumor
activity of FRα CAR T cells in vivo, we inoculated NSG
mice with MDA-231 or MDA-231.FRα cells and allowed
for tumor growth. After 40 days, MDA-231.FRα tumors
were modestly larger than their parental MDA-231 cells
in mice, analogous to the known association between
FRα overexpression and tumor progression [15] and the
reported impact of FRα overexpression on ovarian can-
cer cell proliferation, migration, and invasion [15]. Mice-
bearing established MDA-231.FRα or parental MDA-231
tumors received tail vein injections of 107 CAR+ T cells
on days 40 and 46, and tumor growth was monitored
using caliper measurements and BLI. Consistent with
our initial in vivo assays, FRα CAR T cells modestly de-
layed MDA-231 tumor growth (Fig. 6a, b). However, the
same dose of FRα CAR T cells mediated more effective
tumor regression in mice with MDA-231.FRα tumors,
despite larger initial tumor burden (Fig. 6c, d). On days
60 and 74 after tumor inoculation, the average MDA-
231.FRα tumor volume had decreased by 36 and 58 %,
respectively, while the average MDA-231 tumor volume in-
creased by 107 and 214 %, respectively (Additional file 4:
Figure S4). By comparison, tumor volume increased sharply
after treatment with anti-CD19 CAR T cells (Additional
file 4: Figure S4). BLI confirmed that after treatment
with FRα CAR T cells, mice bearing MDA-231.FRα tu-
mors had less residual tumor burden, compared to mice
with MDA-231 tumor (Fig. 6b, d), despite beginning ther-
apy with greater tumor burden (Fig. 6b, d). Anti-CD19
CAR T cells had no antitumor activity against MDA-231
or MDA-231.FRα tumors in vivo (Fig. 6a, c). These results
suggest that the regression of TNBC mediated by CAR T
cells is dependent on a sufficient level of surface tumor
antigen expression.
Discussion
Although triple-negative breast cancer (TNBC) comprises
approximately 15 % of all breast cancer subtypes, its ag-
gressive biology and lack of specific systemic regimen or
targeted therapy mandates the search for novel treatments
specific for TNBC. Folate receptor-alpha (FRα; FOLR1) is
a glycosyl-phosphatidyl inositol (GPI)-anchored protein
that is overexpressed at both the protein and mRNA levels
in TNBC [16], where it serves a biological role in TNBC
cell growth and folate uptake. Strong FRα immunohisto-
chemical (IHC) staining is highly associated with poor
outcome in breast cancer patients [17], and while approxi-
mately 30 % of breast cancers express FRα, 70–80 % of
stage IV metastatic TNBC tumors express FRα across
multiple subtypes [4]. Importantly, the increased expres-
sion of FRα is associated with a significantly worse clinical
outcome in TNBC [18]. Thus, the rationale for targeting
Fig. 5 FRα CAR T cells preferentially lyse tumor cells overexpressing
FRα. a The MDA-231 cell line was engineered to overexpress FRα
(MDA-231.FRα). b FRα CAR T cells T cells lyse MDA-231.FRα and SKOV3
more efficiently compared to MDA-231 cells. c MDA-231 cells were
engineered to express ~90 % GFP (MDA-231.GFP). MDA-231.GFP cells
were then mixed with MDA-231.FRα cells at a 1:1 ratio (~50 % GFP
expression). The mixed cells were treated with either UNT or FRα CAR
T cells at a 3:1 of E/T ratio for 24 h. UNT T cell treatment had no impact
on the mixed tumor cell (~50 % GFP expression), whereas treatment
with FRα CAR T cells increased the number of GFP (+)-engineered
tumor cells (~85 % GFP expression)
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FRα in TNBC is sound. Interestingly, endogenous im-
mune responses against FRα are evident in cancer pa-
tients. For instance, Knutson et al. [19] demonstrated that
immunity to FRα is prevalent in patients with breast and
ovarian cancers where FRα-reactive lymphocytes having
been identified in patients with these cancers and attempts
to bolster this natural immunity are being investigated in
preclinical and ongoing clinical trials in ovarian cancer
and lung cancer [20, 21]. This led to our hypothesis that
TNBC could be effectively targeted with immune-based
cancer treatment using CAR T cells, an approach that has
shown great utility on the treatment of hematological
malignancy [22]. CAR Tcell therapy represents a rapid ap-
proach to generate and apply a large number of antigen-
specific T cells for the treatment of cancer, and in previous
studies, we developed FRα-specific CAR T cells that dem-
onstrated potent effects on human ovarian cancer in pre-
clinical models [9, 10]. We therefore sought to utilize FRα
CAR T cells to target TNBC.
Consistent with IHC assay results reported by others
[4, 17, 18], we found positive surface expression of FRα
protein on all (5/5) human TNBC cell lines tested by flow
cytometry. FRα expression was largely moderate on these
TNBC lines; however, IHC findings demonstrate that FRα
protein can be expressed at high, intermediate, or low
levels in TNBC, and as with primary breast tumors, the
abundance of FRα mRNA varies among TNBC cell lines,
with a subset expressing high levels [4]. As we showed
earlier, FRα-specific CAR T cells are sensitive in vitro to
FRα protein displayed on the cancer cell surface at a wide
range of levels [9, 10]. In the current study, primary hu-
man T cells expressing a FRα-specific CAR recognized all
human TNBC cell lines expressing FRα at different levels.
FRα-specific T cells exhibited polyfunctionality in their
ability to secrete IFN-γ, TNF-α, and IL-2 upon stimulation
with FRα+ tumor cells. FRα CAR T cells also displayed
potent cytolytic capacity in vitro against FRα+ TNBC cell
lines. These in vitro tumor killing findings further support
Fig. 6 FRα CAR T cells induce rapid tumor regression of MDA-231.FRα in vivo. a-d NSG mice were inoculated with MDA-231 (a, b) or MDA.231.FRα
tumor cells (c, d). Mice bearing established MDA-231.FRα or MDA-231 tumors received tail vein injections of 1 × 107 CAR+ T cells on days 40 and 46,
and tumor growth was monitored by caliper measurements (a, c) and BLI (b, d)
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the notion that FRα has promise as a novel immunother-
apy target for TNBC, which currently lacks effective
targeted therapy. Importantly, two injections of FRα CAR
T cells exhibited in vivo antitumor effects in a highly inva-
sive and metastatic MDA-MB-231 xenograft model of
human TNBC. Given the natural range of FRα protein ex-
pression level in TNBC, we postulated that the response
to CAR T cell therapy may be more pronounced in pa-
tients with tumors expressing higher levels of FRα. Indeed,
our preclinical studies show that the antitumor activity of
FRα CAR T cells correlates with the level of surface anti-
gen expressed by tumor cells, as demonstrated by the
more dramatic tumor regressions mediated by CAR T
cells in mice bearing MDA-231 TNBC tumors in which
FRα was expressed at a high level.
Our results rationalize the application of FRα CAR T
cell therapy in patients with TNBC whose tumors ex-
press FRα, particularly at a high level. It is notable that
the FRα gene is positively regulated by the glucocortic-
oid receptor agonist, dexamethasone, at the transcrip-
tional (P4 promoter) level and this profound regulation
is further potentiated by inhibiting histone deacetylase
(HDAC) [23]. This observation supports the notion that
the efficacy of FRα CAR T cell therapy in TNBC patients
with low to intermediate tumoral FRα levels may be im-
proved in combination with dexamethasone and HDAC
inhibitors that enhance FRα gene expression; however,
additional preclinical studies of cell surface expression of
FRα would be required to confirm this finding in vitro
and in vivo, as well as their effects on normal tissue
organ expression.
As an alternative approach to improve CAR T cell
therapy for TNBC, simultaneous co-targeting of two
different tumor-associated antigens may be applied to
broaden the immune response and induce tumor elim-
ination. For instance, like FRα, mesothelin, another
GPI-linked cell surface glycoprotein present on mesothelial
cells, is overexpressed in TNBC and has been shown to be
an attractive immunotherapy target for CAR T cells [24].
We previously constructed a fully human anti-mesothelin
CAR and showed that CAR-redirected T cells efficiently
kill mesothelin-expressing tumors in vitro and in vivo [25].
Therefore, co-administration of FRα CAR T cells and
mesothelin CAR T cells may provide superior antitumor
effects in TNBC and also address potential issues of tumor
antigen heterogeneity and antigen loss, which has been
previously reported [26, 27]. In this line, we have previously
established proof of principle for the application of bispeci-
fic CAR T cells with specificity for both mesothelin and
FRα [28]. However, Anurathapan et al. [29] demonstrated
optimal antitumor effects using two different antigen-
specific CARs simultaneously, though this was insufficient
to achieve a complete response. Small numbers of residual
tumor cells were observed that appeared to express the
targeted antigens and were resistant to repetitive T cell
treatment, likely due to the low level of antigen expression
determining tumor susceptibility to CAR T cells. Simi-
larly, in a multicenter trial [30] of a novel FRα-targeted
agent (EC145) in advanced, FRα-positive adenocarcinoma
of the lung, there was an overall survival advantage and
superior clinical benefit response for patients who had
high expression of FRα on their tumors compared with
those who had tumors with intermediate FRα expres-
sion. Based on these results, a phase II trial (clinical-
trials.gov/NCT01577654) evaluating the activity of
EC145 versus EC145 plus docetaxel versus docetaxel
alone in FRα high tumors has been initiated. Collectively,
results from these studies suggest that pre-selection of pa-
tients with a high-level antigen expression could improve
clinical response rates.
In the clinic, another T cell-based immunotherapy ap-
proach utilizing bispecific T cell engager (BiTE) is also
under investigation [31, 32]. BiTEs provide a conventional
drug approach in terms of storage, dosage, and delivery
system; however, BiTEs have a short half-life and have to
be given as a continuous infusion, which can be associated
with systemic toxicities [33]. In addition, BiTEs lack active
biodistribution once infused and may not penetrate tissue
planes [33]. Compared with the BiTE approach, CAR T
cell therapy has several advantages for TNBC and other
cancers. CAR T cells can recognize and lyse cells bearing a
very low level of target antigen, and CAR T cells can per-
sist long term in vivo. Since our human FRα CAR T cells
do not cross-react against mouse FRα protein, the poten-
tial for toxicity of this approach in the TNBC mouse
model cannot be determined. Importantly, however, vari-
ous strategies are being developed to create safer, regulata-
ble CARs that control and/or minimize potential toxicity
[34, 35].
While increased expression of FRα is associated with
a poor clinical outcome in TNBC [17], FRα expression
may vary by TNBC subtype and be associated with dis-
ease stage. Future studies will be required to determine
the minimal and maximal threshold of FRα expression
for activation and effective lysis by FRα CAR T cells
upon stimulation with the TNBC cell lines or autolo-
gous tumor cells. Such results might aid in determining
which patients may best benefit from FRα CAR T cell
therapy and help determine the potential for off-
tumor targeting of healthy tissues that may express
low levels of antigen.
Conclusion
We report the first demonstration of an in vivo antitu-
mor response against established human TNBCxeno-
grafts using FRα-redirected CAR T cell therapy, with
increased sensitivity observed against tumors bearing
higher FRα protein levels. We therefore conlude that
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pateints with TNBC that expresses a high level of FRα
protein may benefit from FRα-redirected CAR T cell
therapy. More so, our preclinical studies serve to further
accelerate the translation of FRα-targeted immunother-
apies, including FRα CAR T cell therapy, to the clinic for
TNBC.
Additional files
Additional file 1: Figure S1. Expression of FRα in enzymatically digested
MDA-231 and cell lines and correlation with IFN-γ secretion. FRα expression
was determined using BD Quanti-Brite beads. The number of receptors per
cell was calculated used at a 1:1 PE/protein ratio for the quantitative analysis
of surface FRα expression. FRα antigen number per tumor cell was
calculated by comparing the mean fluorescence intensity (MFI) versus
the number of known PE molecules per bead. T47D and MDA-231
exhibited the highest number of FRα receptors per cell and AE17 mouse
mesothelioma cell line displaying the lowest number of receptors per cell
(A). Using a linear regression fitted line, the correlation between the Frα
receptors per cell and IFN-γ secretion was calculated (B). (TIF 51 kb)
Additional file 2: Figure S2. MDA-231 tumors retained a stable FRα
expression profile after UNT, CD19 CAR, or FRα CAR T cell treatment. On
day 73, mice bearing MDA-231 tumors were sacrificed and tumors were
collected and cut up in RPMI 1640, washed, and centrifuged at room
temperature at 800 rpm for 5 min and then resuspended in enzymatic
digestion buffer (collagenase [0.2 mg/mL] and DNase [30 units/mL] in
RPMI 1640) for overnight digestion at room temperature. FRα-specific
mAb MOv18 was used to measure FRα expression on MDA-231 tumors
treated with different T cells. (TIF 51 kb)
Additional file 3: Figure S3. FRα CAR T cells induced SKOV3 ovarian
tumor rapid regression in vivo. NSG mice were inoculated with SKOV3
ovarian cancer tumor cells. Mice bearing established SKOV3 tumors
received tail vein injections of 107 CAR+ T cells on days 40 and 46 and
tumor growth was monitored by caliper measurements. (TIF 140 kb)
Additional file 4: Figure S4. Tumor volume fold changes after CAR T
cell treatment on days 60 and 74. NSG mice were inoculated with MDA-231
or MDA-231. FRα tumor cells. Mice bearing established MDA-231.FRα or
MDA-231 tumors received tail vein injections of 1 × 107 CAR+ T cells on days
40 and 46, and tumor growth was monitored by caliper measurements.
(TIF 37 kb)
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